Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension

Hypertension

Volumn 66, Issue 4, 2015, Pages 767-775

  Martínez Martínez, Ernesto ^a   Calvier, Laurent ^b,c   Fernández Celis, Amaya ^a   Rousseau, Elodie ^b,c   Jurado López, Raquel ^d   Rossoni, Luciana V ^e   Jaisser, Frederic ^b,c,f   Zannad, Faiez ^b,c   Rossignol, Patrick ^b,c   Cachofeiro, Victoria ^d   López Andrés, Natalia ^a,b,c  

^a Atención Primaria Y Promoción de La Salud   (Spain)

^b UNIVERSITÉ DE LORRAINE   (France)

^c French Clinical Research Infrastructure Network (F CRIN)   (France)

^d SCHOOL OF MEDICINE   (Spain)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

aldosterone; fibrosis; galectin 3; hypertension; inflammation

Indexed keywords

ALDOSTERONE; C REACTIVE PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGENASE 3; FIBRONECTIN; GALECTIN 3; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MINERALOCORTICOID RECEPTOR; MODIFIED CITRUS PECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PECTIN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MINERALOCORTICOID ANTAGONIST;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDITIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL HYPERALDOSTERONISM; EXPERIMENTAL MODEL; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; HYPERALDOSTERONISM; HYPERTENSION; IN VITRO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; FIBROSIS; METABOLISM; MYOCARDITIS; PATHOLOGY; WISTAR KYOTO RAT; WISTAR RAT;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; GALECTIN 3; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDITIS; RATS; RATS, INBRED WKY; RATS, WISTAR; SPIRONOLACTONE;

EID: 84941217103     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05876     Document Type: Article

References (28)

1. Díez J, Arterial hypertension in patients with heart failure. Heart Fail Clin 2014 10 233 242. doi: 10.1016/j.hfc.2013.12.004
2. Cha JH, Wee HJ, Seo JH, Ahn BJ, Park JH, Yang JM, Lee SW, Kim EH, Lee OH, Heo JH, Lee HJ, Gelman IH, Arai K, Lo EH, Kim KW, AKAP12 mediates barrier functions of fibrotic scars during CNS repair. PLoS One 2014 9 e94695. doi: 10.1371/journal.pone.0094695
3. Vanhoutte D, van Almen GC, Van Aelst LN, Van Cleemput J, Droogné W, Jin Y, Van de Werf F, Carmeliet P, Vanhaecke J, Papageorgiou AP, Heymans S, Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. Eur Heart J 2013 34 1930 1941. doi: 10.1093/eurheartj/ehs375
4. Rogerson FM, Fuller PJ, Mineralocorticoid action. Steroids 2000 65 61 73
5. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G, Entman M, Carabello BA, Roberts R, Marian AJ, Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004 109 1284 1291. doi: 10.1161/01.CIR.0000121426.43044.2B
6. Sowers J, Tuck M, Asp ND, Sollars E, Plasma aldosterone and corticosterone responses to adrenocorticotropin, angiotensin, potassium, and stress in spontaneously hypertensive rats. Endocrinology 1981 108 1216 1221. doi: 10.1210/endo-108-4-1216
7. Zia AA, Kamalov G, Newman KP, McGee JE, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT, From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res 2010 33 1091 1101. doi: 10.1038/hr.2010.159
8. Iacobone M, Citton M, Viel G, Rossi GP, Nitti D, Approach to the surgical management of primary aldosteronism. Gland Surg 2015 4 69 81. doi: 10.3978/j.issn.2227-684X.2015.01.05
9. Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L, Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 2014 63 797 803. doi: 10.1161/HYPERTENSIONAHA.113.02883
10. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 348 1309 1321. doi: 10.1056/NEJMoa030207
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 341 709 717. doi: 10.1056/NEJM199909023411001
12. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011 364 11 21. doi: 10.1056/NEJMoa1009492
13. Martínez-Martínez E, Jurado-López R, Valero-Muñoz M, Bartolomé MV, Ballesteros S, Luaces M, Briones AM, López-Andrés N, Miana M, Cachofeiro V, Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. J Hypertens 2014 32 1104 14; discussion 1114. doi: 10.1097/HJH.0000000000000149
14. Thijssen VL, Hulsmans S, Griffioen AW, The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 2008 172 545 553. doi: 10.2353/ajpath.2008.070938
15. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR, Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008 28 433 440. doi: 10.1161/ATVBAHA.107.159160
16. Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P, Association of galectin-3 and fibrosis markers with long-Term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012 14 74 81. doi: 10.1093/eurjhf/hfr151
17. Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, Plebani M, Rossi GP, Galectin-3 predicts long-Term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015 35 725 732. doi: 10.1161/ATVBAHA.114.304964
18. Glinsky VV, Raz A, Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res 2009 344 1788 1791. doi: 10.1016/j.carres.2008.08.038
19. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N, Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013 33 67 75. doi: 10.1161/ATVBAHA.112.300569
20. Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N, The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 2015 3 59 67. doi: 10.1016/j.jchf.2014.08.002
21. Azibani F, Benard L, Schlossarek S, Merval R, Tournoux F, Fazal L, Polidano E, Launay JM, Carrier L, Chatziantoniou C, Samuel JL, Delcayre C, Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 2012 59 1179 1187. doi: 10.1161/HYPERTENSIONAHA.111.190512
22. Colnot C, Fowlis D, Ripoche MA, Bouchaert I, Poirier F, Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn 1998 211 306 313. doi: 10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L
23. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, van Veldhuisen DJ, Bank RA, van Gilst WH, Silljé HH, de Boer RA, Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013 6 107 117. doi: 10.1161/CIRCHEARTFAILURE.112.971168
24. Shen JZ, Young MJ, Corticosteroids, heart failure, and hypertension: a role for immune cells? Endocrinology 2012 153 5692 5700. doi: 10.1210/en.2012-1780
25. Bunda S, Wang Y, Mitts TF, Liu P, Arab S, Arabkhari M, Hinek A, Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2009 284 16633 16647. doi: 10.1074/jbc.M109.008748
26. Bell D, Kelso EJ, Argent CC, Lee GR, Allen AR, McDermott BJ, Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive rat. Cardiovasc Pathol 2004 13 71 78. doi: 10.1016/S1054-8807(03)00135-2
27. Luft FC, Mervaala E, Müller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H, Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999 33 1 Pt 2 212 218
28. Savoia C, Schiffrin EL, Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006 15 152 158. doi: 10.1097/01.mnh.0000203189.57513.76